AR-C118925XX

AR-C118925XX is a selective P2Y2 receptor antagonist. AR-C118925XX inhibits ATP-induced IL-6 production and phosphorylation of p38. AR-C118925XX also inhibits Bleomycin (HY-108345) -induced dermal fibrosis in mice. AR-C118925XX also inhibits ATP-induced tumor growth[1][2].

Product Specifications

CAS Number

[216657-60-2]

UNSPSC

12352005

Hazard Statement

H228, H315, H319

Target

P2Y Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ar-c118925xx.html

Purity

99.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(CN2C=C(C3C4=CC=C(C)C=C4C=CC5=CC(C)=CC=C53)C(NC2=O)=S)O1)NC6=NN=NN6

Molecular Formula

C28H23N7O3S

Molecular Weight

537.59

Precautions

H228, H315, H319

References & Citations

[1]Perera LMB, et al. The Regulation of Skin Fibrosis in Systemic Sclerosis by Extracellular ATP via P2Y2 Purinergic Receptor. J Invest Dermatol. 2019 Apr;139 (4) :890-899. |[2]Dong CR, et al. AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer. Carcinogenesis. 2022 Dec 5:bgac095.